Michael Brands

3.0k total citations · 1 hit paper
46 papers, 2.1k citations indexed

About

Michael Brands is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Michael Brands has authored 46 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Molecular Biology, 14 papers in Oncology and 10 papers in Organic Chemistry. Recurrent topics in Michael Brands's work include Cancer-related Molecular Pathways (8 papers), Microtubule and mitosis dynamics (6 papers) and Synthesis and biological activity (5 papers). Michael Brands is often cited by papers focused on Cancer-related Molecular Pathways (8 papers), Microtubule and mitosis dynamics (6 papers) and Synthesis and biological activity (5 papers). Michael Brands collaborates with scholars based in Germany, United States and France. Michael Brands's co-authors include Franz von Nussbaum, Dieter Häbich, Stefan Weigand, Berthold Hinzen, John E. Hall, Karl Ziegelbauer, Magdalena Alonso‐Galicia, Dion Zappe, Lars Wortmann and Dominik Mumberg and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Angewandte Chemie International Edition.

In The Last Decade

Michael Brands

44 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antibacterial Natural Products in Medicinal Chemistry—Exodus or Revival?

2006 530 citations Franz von Nussbaum, Michael Brands et al. Angewandte Chemie International Edition profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Brands Germany	20	1.1k	601	360	353	201	46	2.1k
Amareshwar T.K. Singh United States	17	1.2k 1.1×	208 0.3×	458 1.3×	143 0.4×	91 0.5×	32	2.3k
Yamei Yu China	27	842 0.8×	377 0.6×	207 0.6×	170 0.5×	168 0.8×	81	2.0k
Walter E. DeWolf United States	26	984 0.9×	620 1.0×	163 0.5×	147 0.4×	88 0.4×	50	1.9k
Qian Lei China	29	1.1k 0.9×	320 0.5×	249 0.7×	115 0.3×	145 0.7×	85	2.0k
Rosanna Filosa Italy	30	796 0.7×	732 1.2×	253 0.7×	272 0.8×	107 0.5×	83	2.4k
Yanna Cheng China	29	933 0.8×	153 0.3×	266 0.7×	156 0.4×	122 0.6×	66	2.0k
Nam Doo Kim South Korea	32	1.8k 1.6×	454 0.8×	384 1.1×	159 0.5×	260 1.3×	102	2.9k
Zhihua Sui United States	28	949 0.8×	1.5k 2.5×	215 0.6×	297 0.8×	92 0.5×	123	2.7k
Milica Pešić Serbia	29	1.3k 1.1×	308 0.5×	476 1.3×	144 0.4×	101 0.5×	135	2.4k
Guy G. Chabot France	32	1.6k 1.4×	481 0.8×	712 2.0×	476 1.3×	69 0.3×	67	3.1k

Countries citing papers authored by Michael Brands

Since Specialization

Citations

This map shows the geographic impact of Michael Brands's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Brands with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Brands more than expected).

Fields of papers citing papers by Michael Brands

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Brands. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Brands. The network helps show where Michael Brands may publish in the future.

Co-authorship network of co-authors of Michael Brands

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Brands. A scholar is included among the top collaborators of Michael Brands based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Brands. Michael Brands is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

O’Herron, Philip, et al.. (2025). Blood pressure variability compromises vascular function in middle-aged mice. eLife. 14. 1 indexed citations

Luh, Laura M., U. Scheib, Katrin Juenemann, et al.. (2020). Beute für das Proteasom: Gezielter Proteinabbau aus medizinalchemischer Perspektive. Angewandte Chemie. 132(36). 15576–15595. 6 indexed citations

Luh, Laura M., U. Scheib, Katrin Juenemann, et al.. (2020). Prey for the Proteasome: Targeted Protein Degradation—A Medicinal Chemist's Perspective. Angewandte Chemie International Edition. 59(36). 15448–15466. 133 indexed citations

Wengner, Antje M., Gerhard Siemeister, Ulrich Lücking, et al.. (2019). The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models. Molecular Cancer Therapeutics. 19(1). 26–38. 145 indexed citations

Karlsson, Jenny, Christine Ellingsen, Véronique Cruciani, et al.. (2019). Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model. Pharmaceuticals. 12(4). 155–155. 29 indexed citations

Siemeister, Gerhard, Anne Mengel, Amaury E. Fernández‐Montalván, et al.. (2018). Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo. Clinical Cancer Research. 25(4). 1404–1414. 53 indexed citations

Lefranc, Julien, Antje M. Wengner, Lars Wortmann, et al.. (2017). Abstract 983: Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models. Cancer Research. 77(13_Supplement). 983–983. 12 indexed citations

Wengner, Antje M., Gerhard Siemeister, Marcus Koppitz, et al.. (2016). Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity. Molecular Cancer Therapeutics. 15(4). 583–592. 85 indexed citations

Héroult, Mélanie, Peter Ellinghaus, Dirk Brohm, et al.. (2014). Abstract 1739: Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial. Cancer Research. 74(19_Supplement). 1739–1739. 9 indexed citations

10.

Jèmaà, Mohamed, Lorenzo Galluzzi, Oliver Kepp, et al.. (2013). Characterization of novel MPS1 inhibitors with preclinical anticancer activity. Cell Death and Differentiation. 20(11). 1532–1545. 83 indexed citations

11.

Brands, Michael. (2012). Chronic Blood Pressure Control. Comprehensive physiology. 2(4). 2481–2494. 3 indexed citations

12.

Nussbaum, Franz von, Michael Brands, Berthold Hinzen, Stefan Weigand, & Dieter Häbich. (2006). Antibacterial Natural Products in Medicinal Chemistry—Exodus or Revival?. Angewandte Chemie International Edition. 45(31). 5072–5129. 530 indexed citations breakdown →

13.

Brands, Michael, Jens‐Kerim Ergüden, Kentaro Hashimoto, et al.. (2005). Novel, selective indole-based ECE inhibitors: Lead optimization via solid-phase and classical synthesis. Bioorganic & Medicinal Chemistry Letters. 15(19). 4201–4205. 15 indexed citations

14.

Tang, Jiping, et al.. (2005). Decreased RhoA expression in myocardium of diabetic rats. Canadian Journal of Physiology and Pharmacology. 83(8-9). 775–783. 5 indexed citations

15.

Brands, Michael, Jens‐Kerim Ergüden, Kentaro Hashimoto, et al.. (2005). Selective Indole‐Based ECE Inhibitors: Synthesis and Pharmacological Evaluation. ChemMedChem. 1(1). 96–105. 8 indexed citations

16.

Freiberg, Christoph, Nina Brunner, Guido Schiffer, et al.. (2004). Identification and Characterization of the First Class of Potent Bacterial Acetyl-CoA Carboxylase Inhibitors with Antibacterial Activity. Journal of Biological Chemistry. 279(25). 26066–26073. 168 indexed citations

17.

Brands, Michael, Rainer Endermann, Reinhold Gahlmann, Jochen Krüger, & Siegfried Raddatz. (2003). Dihydropyrimidinones—a new class of anti-Staphylococcal antibiotics. Bioorganic & Medicinal Chemistry Letters. 13(2). 241–245. 58 indexed citations

18.

Brands, Michael, et al.. (2003). Pyrimidinone antibiotics—heterocyclic analogues with improved antibacterial spectrum. Bioorganic & Medicinal Chemistry Letters. 13(16). 2641–2645. 28 indexed citations

19.

Brands, Michael, et al.. (1994). Exaggerated Pressor and Chronotropic Response to Chronic Hyperinsulinemia in SH Versus WKY Rats. American Journal of Hypertension. 7(1). 75–81. 23 indexed citations

20.

Verburg, Kenneth M., et al.. (1989). Cardiovascular and renal effects of calcitonin gene-related peptide in hypertensive dogs. Peptides. 10(3). 663–669. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact